diabetes
Conditions
Interventions
Non-intervention group:All newly diagnosed elderly diabetic populations enrolled were not typed and were uniformly intervened with traditional treatment modalities based on existing guideline requirem
Precision Typing Intervention Group:The precise typing intervention group was conducted in three Hospitals, and the enrolled patients were stratified and typed for precise individualised treatment. Th
2. for diabetes mellitus mainly characterised by insulin resistance, metformin combined with SGLT-2i and lifestyle improvement is recommended based on lifestyle improvement. Lifestyle improvement meth
? Reduce the total calories in the diet by at least 400-500kcal per day (1kcal=4.184kJ), and those who are overweight or obese should reduce the total calories by 500-750kcal
? Saturated fatty acid intake accounted for the proportion of total fatty acid intake. Fatty acid intake accounts for less than 30% of the total fatty acid intake
the total amount of salt per person per day does not exceed 5g
? moderate-intensity physical activity should be maintained at least 150min/week. 3. diabetes mellitus with obesity as
Sponsors
Beijing hospital
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Within 3 years of the time of diagnosis of diabetes and the most applied monotherapy for diabetes mellitus; (2) Age > 65 years; age 65-80 years; (3) Stratified according to the "Chinese Guidelines for Diabetes in the Elderly (2021 edition)", patients with results of "group 1" and "group 2" (i.e., health grades of "good" and "moderate"); (4) Patients with diabetes in the designated hospitals who agree to participate in the clinical trial and are able to follow up in a timely manner; (5) Have the results of glycated haemoglobin, pancreatic islet function and blood biochemistry tests within three months at the time of enrolment; (6) Signed the informed consent form and volunteered to undergo the trial.
Exclusion criteria
Exclusion criteria: (1) Diagnosis of diabetes mellitus for more than 3 years or concurrent use of more than 1 hypoglycaemic drug; (2) Patients stratified according to the "China Diabetes Guidelines for the Elderly (2021 Edition)", and the result is "group 3" (i.e., the health grade is "poor"); (3) Combined serious cardiovascular and cerebrovascular diseases; (4) Critically ill patients; (5) Patients with chronic kidney disease; (6) Patients with mental illnesses, etc., who cannot sign informed consent; (7) Those who refused to participate in the survey follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| height;weight;Waist-hip circumference;pulse;Blood pressure;urine protein;urine acetone bodies;glutamic-pyruvic transaminase;glutamic oxalacetic transaminase;total bilirubin;alkaline phosphatase;urea nitrogen;creatinine;Urine albumin creatinine ratio;uric acid;triglyceride;cholesterol;Low density lipoprotein cholesterol;High density lipoprotein cholesterol;Glycosylated hemoglobin;Fasting blood glucose;Fasting insulin;Fasting c-peptide;Type B natriuretic peptide; | — |
Secondary
| Measure | Time frame |
|---|---|
| electrocardiography;specific gravity of urine; | — |
Countries
China
Contacts
Public ContactGuo lixin
Beijing hospital
Outcome results
None listed